Schedule of Noncontrolling Interest of Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
NCI – equity (deficit) – beginning of period			$ 17,752	$ (2,369)	$ (2,369)
Investment in Veris Health Inc.					6
Net loss attributable to NCI – Lucid Diagnostics Inc.	$ (3,806)	$ (1,441)	(10,143)	$ (3,318)
Impact of subsidiary equity transactions			(1,375)		16,760
Lucid Diagnostics Inc. proceeds from Committed Equity Facility, net of deferred financing charges			1,767
Lucid Diagnostics Inc. issuance of common stock for settlement of APA-RDx installment payment			427
Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise			694
Lucid Diagnostics Inc. Employee Stock Purchase Plan Purchase			109
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan			10,371		9,134
Stock-based compensation expense - Veris Health Inc. 2021 Equity Plan			6
NCI – equity (deficit) – end of period	$ 19,608		19,608		17,752
Lucid Diagnostics Inc [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Net loss attributable to NCI – Lucid Diagnostics Inc.			(9,032)		(5,779)
Solys Diagnostics Inc [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Net loss attributable to NCI – Solys Diagnostics Inc.			(6)
Veris Health Inc [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Net loss attributable to NCI – Veris Health Inc.			$ (1,105)